High materiality7/10
Raymond James Downgrades Ascendis Pharma (ASND) to Outperform
Why it may matterVerify against the original reporting
Buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Raymond James assigns an Outperform rating to ASND with a target of $287; current price $264.92.
- ASND assigned Outperform; target $287; price $264.92.
Key facts
- 01
Target: $287
- 02
Posted price: $264.92
- 03
Analyst firm: Raymond James
- 04
Analyst: Martin Auster
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.